Pembrolizumab for cutaneous squamous cell carcinoma: Report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation
Author:
Publisher
Elsevier BV
Subject
Dermatology
Reference10 articles.
1. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab;Stevenson;JAMA Dermatol,2017
2. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma;Mahoney;Clin Ther,2015
3. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients;Tetzlaff;J Immunother Cancer,2018
4. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma;Migden;N Engl J Med,2018
5. REGN2810: A fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—initial safety and efficacy from expansion cohorts (ECs) of phase I study;Papadopoulos;J Clin Oncol,2017
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment—A Cross-Sectional Study;Cells;2024-06-03
2. Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia;International Journal of Molecular Sciences;2023-07-06
3. Programmed cell death-1 receptor-mediated regulation of Tbet + NK1.1 − innate lymphoid cells within the tumor microenvironment;Proceedings of the National Academy of Sciences;2023-04-25
4. Programmed cell death-1 receptor mediated regulation of Tbet+ NK1.1− Innate Lymphoid Cells within the Tumor Microenvironment;2022-09-25
5. Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome;Annals of Medicine & Surgery;2022-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3